1. Naeim A, Dy SM, Lorenz KA, Sanati H, Walling A, Asch SM. Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol. 2008;26:3903–10.
2. Schnell F. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8(2): 187–98.
3. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005;41:199–205.
4. Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, et al. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer. 2007;15: 179–85.
5. de Wit R, Aapro M, Blower PR. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? Cancer Chemother Pharmacol. 2005;56:231–8.
6. Kaiser R, Tremblay PB, Sezer O, Possinger K, Roots I, Brockmoller J. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics. 2004; 14:271–8.
7. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17:20–8.
8. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–47.
9. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4: 191–6.
10. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neurophar- macology to clinical investigations. Cancer J. 2006;12:341–7.
11. Rang H, Dale M, Ritter J, Flower R. Pharmacology. 6 th, 391. 2007. Elsevier. ISBN: 9780443050473.
12. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–94.
13. Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101:143–50.
14. Johnston KD. The potential for mu-opioid receptor agonists to be anti-emetic in humans: a review of clinical data. Acta Anaesthesiol Scand. 2010;54:132–40.
15. Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol. 2006;19:606–11.
16. Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics. 2008;9: 501–4.
17. Herrstedt J. Antiemetic research: a look to the future. Support Care Cancer. 1998;6:8–12.
18. Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. 2002;8:405–14.
19. de Wit R. Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer. 2003;88:1823–7.
20. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, et al. Patient-tailored antiemetic treatment with 5-hydroxytryp- tamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002;20:2805–11.
21. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol. 2004;44:520–31.
22. McEvoy GK. AHFS Drug Information. 2299, 2798,2800, 2850. 2004. American Society of Health System Pharmacist, Bethesda. ISBN:1585280585.
23. Page C, Curtis M, Sutter M, Walker M, Hoffman B. Integrated Pharmacology. London: Mosby International, 2002. ISBN: 978-0723432210.
24. Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastropr- okinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002;30: 336–43.
25. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37:435–56.
26. Herfindall E, Gourley D. Textbook of therapeutics, drug and dis- ease management. Philadelphia: Lippincott Williams & Wilkins; 2000. ISBN: 9780781724159.
27. Williams D, Lemke T. Foye’s principal of medicinal chemistry. Baltimore: Lippincott Williams & Wilkins; 2002. ISBN: 978-0683 307375.
28. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci. 2008;1139:434–49.
29. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14:85–93.
30. Slatkin NE. Cannabinoids in the treatment of chemotherapy- induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007;5:1–9.